Dylann Cohn-Emery

Articles

Earlier Use of Acalabrutinib Associated With Improved Survival in CLL

June 14th 2024

Earlier use of acalabrutinib was associated with improved survival in patients with chronic lymphocytic leukemia.

DFF332 Elicits Efficacy and Is Safe in Advanced Clear Cell RCC

June 1st 2024

The small molecule inhibitor DFF332 elicited clinical activity and had a tolerable safety profile in patients with advanced clear cell renal cell carcinoma.

Belumosudil Plus Ruxolitinib Displays Activity in Steroid-Refractory/-Dependent cGVHD

February 23rd 2024

Belumosudil plus ruxolitinib elicited responses with acceptable tolerability in patients with chronic graft-vs-host disease.

Network Meta-Analysis Sheds Light on Efficacy of Lenvatinib Plus Pembrolizumab Vs SOC in Advanced RCC

January 27th 2024

Lenvatinib/pembrolizumab shows a trend of improved PFS and overall response rate vs standard immunotherapies in advanced renal cell carcinoma.

Capivasertib Maintains QOL Benefit Vs Placebo in HR+/HER2– Advanced Breast Cancer

December 6th 2023

Capivasertib plus fulvestrant did not negatively affect quality of life compared with placebo plus fulvestrant in patients with aromatase inhibitor–resistant, hormone receptor–positive, HER2-negative advanced breast cancer.

Exploratory Analysis Shows Continued Lenvatinib After Pembrolizumab/Lenvatinab Provides Clinical Benefit in Previously Treated Endometrial Cancer

October 23rd 2023

Continued treatment with lenvatinib monotherapy after the completeion of combination therapy with pembrolizumab and lenvatinib resulted in sustained clinical benefit vs chemotherapy alone in patients with previously treated advanced endometrial cancer.

CD38/48 Upregulation With Tazemetostat May Overcome Daratumumab Resistance in Multiple Myeloma

September 29th 2023

The EZH2 inhibitor tazemetostat may mimic the role of the KDM6A gene in upregulating CD38 and CD48 expression, suggesting that this agent could restore responses to daratumamab in patients with multiple myeloma, according to a presentation at the 20th International Myeloma Society Annual Meeting.

Data for Luspatercept Highlight Evolving Treatment Landscape in Lower-Risk MDS

September 19th 2023

Uwe Platzbecker, MD, discusses how the FDA approval of luspatercept for the treatment of anemia in patients who have not had prior treatment with erythropoiesis-stimulating agent and may require regular red blood cell transfusions could change the sequencing of agents for this patient population.

Interim Results Show Durable Response With Dato-DXd in Advanced NSCLC

September 11th 2023

The addition of datopotamab deruxtecan to durvalumab, with or without carboplatin, demonstrated favorable efficacy and safety in patients with advanced or metastatic non–small cell lung cancer, according to an interim analysis of the phase 1b TROPION-Lung04 trial.

Quizartinib Plus Induction Chemotherapy Provides Survival Benefit in FLT3 ITD–Mutated AML

September 8th 2023

The addition of quizartinib to induction and consolidation chemotherapy, followed by single-agent quizartinib for up to 36 cycles, improved survival outcomes vs placebo in patients with FLT3 ITD–mutated, newly diagnosed acute myeloid leukemia.

MASP-3 Inhibitor Demonstrates Clinical Efficacy in Paroxysmal Nocturnal Hemoglobinuria

June 11th 2023

OMS906, a MASP-3 inhibitor, normalized hemoglobin, lactate dehydrogenase, and reticulocytes levels in patients with paroxysmal nocturnal hemoglobinuria.

Epcoritamab Plus Rituximab/Lenalidomide Produces Responses in High-risk R/R Follicular Lymphoma

June 7th 2023

Treatment with the combination of epcoritamab, rituximab, and lenalidomide led to responses and durable remissions in patients with relapsed/refractory follicular lymphoma.

Ruxolitinib Induces High Responses in SR-aGVHD, Regardless of Cytopenias

February 17th 2023

The presence of cytopenias did not affect the favorable and durable responses seen with ruxolitinib vs best available therapy in patients with steroid-refractory acute graft-vs-host disease.

Treatment Approaches Should Remain Consistent Across Late and Classic aGVHD

February 17th 2023

Timing of severe symptom onset is the only distinct difference between late and classic acute graft-vs-host disease, and long-term outcomes were similar between the two types of disease.

Newer Therapies Demonstrate Real-world Benefit Vs Sorafenib in First-line HCC

January 21st 2023

Newer frontline therapies demonstrated a real-world improvement in survival and responses compared with sorafenib in patients with hepatocellular carcinoma.

Lintuzumab-Ac225 With Intensive Chemo Has Encouraging Efficacy Signal in High-risk AML

December 10th 2022

Sequential administration of lintuzumab-Ac225 after salvage chemotherapy proved to be safe and feasible, and to result in high response and minimal residual disease negativity rates in high-risk patients with relapsed/refractory acute myeloid leukemia.

Neoadjuvant Platinum Plus Standard Chemotherapy Improves Survival in TNBC

December 10th 2022

The addition of carboplatin to taxane-anthracycline chemotherapy led to a significant improvement in event-free survival and overall survival as neoadjuvant therapy in patients with operable and locally advanced triple-negative breast cancer.

Adjuvant Canakinumab Misses DFS Primary End Point in NSCLC

September 12th 2022

Patients with completely resected non–small cell lung cancer did not derive a significant benefit with adjuvant canakinumab vs placebo.

Neoadjuvant Nivolumab/Ipilimumab Elicits Promising Pathologic Responses in dMMR Colon Cancer

September 11th 2022

Four weeks of treatment with nivolumab plus ipilimumab elicited major pathologic responses in 95% of patients with mismatch repair–deficient colon cancer.

Isatuximab Plus Kd Demonstrates Deep Responses in Relapsed Multiple Myeloma

August 27th 2022

The addition of isatuximab to carfilzomib and dexamethasone elicited a clinically meaningful improvement in depth of response in patients with relapsed multiple myeloma.